Unbiased AI-powered news
Sony has invested $34 million to repurpose its Thalgau factory from making PlayStation discs to producing optical microlenses. The change follows the company's announcement that it will stop producing disc-based games in January 2028.
morningstaronline.co.ukSony has already spent €30 million converting its Thalgau, Austria, disc factory into a facility for optical microlenses. The plant currently produces 600,000 discs daily, half of them for PlayStation games. The company told workers on July 1 that disc output will fall to 10 percent of current levels by 2028.
Sony DADC CEO Dietmar Tanzer said the firm plans to retain all 300 employees and begin microlens production next year.
Background on the Thalgau Facility The Thalgau site serves as the headquarters for Sony DADC. It previously supplied discs worldwide, including a now-closed Indiana plant that manufactured 23 billion discs between 1983 and 2022. Sony DADC has produced an additional 3.4 billion discs since the Indiana closure.
Management informed ORF Salzburg that the conversion work had been underway for some time before the July announcement.
Optical microlenses are used in camera sensors, AR/VR headsets, fiber optic networks, and medical devices. The company expects the new production line to replace most of the lost disc volume. " — Dietmar Tanzer, Sony DADC CEO, July 2026 (ORF Salzburg via Engadget) The shift aligns with Sony's earlier decision to move PlayStation games to an all-digital model beginning in January 2028.
ndtv.comTesla recorded lower sales in the United States during the first half of 2026. European deliveries rose sharply after price cuts and higher fuel prices linked to the Iran war.
The Court of Justice of the European Union confirmed a 4.1 billion euro penalty against Google for bundling its search and browser apps as defaults on Android devices. The ruling ends Google's appeals process that began after the original 2018 decision.
pbs.orgThe Centers for Medicare and Medicaid Services last month proposed rules to group reformulated drugs with their originals for negotiation eligibility. The changes target biologics switched from intravenous to subcutaneous forms and would take effect with the 2029 price applicabil…